ERYTECH Pharma S.A.
ERYP · NASDAQ
12/31/2022 | 9/30/2022 | 6/30/2022 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | -$0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | -$0 |
| Operating Expenses | -$0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$0 | $0 | $0 | $0 |
| Pre-Tax Income | $0 | -$0 | $0 | -$0 |
| Tax Expense | -$0 | $0 | $0 | -$0 |
| Net Income | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| EPS | 0.19 | -0.17 | 0.35 | -0.38 |
| % Growth | 211.8% | -148.6% | 192.1% | – |
| EPS Diluted | 0.19 | -0.17 | 0.35 | -0.38 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | -$0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |